SUTRO BIOPHARMA INC (STRO) Stock Price, Quote, News and Overview
NASDAQ:STRO - Nasdaq - US8693671021 - Common Stock - Currency: USD
STRO Quote, Performance and Key Statistics
1.77
-0.06 (-3.28%)
The current stock price of STRO is 1.77 USD. In the past month the price decreased by -12.81%. In the past year, price decreased by -60.84%.
STRO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About STRO
Company Profile
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 306 full-time employees. The company went IPO on 2018-09-27. The firm is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. The company also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Company Info
SUTRO BIOPHARMA INC
111 Oyster Point Blvd.
South San Francisco CALIFORNIA 94080 US
CEO: William J. Newell
Employees: 304
Company Website: https://www.sutrobio.com/
Investor Relations: https://ir.sutrobio.com/
Phone: 16503928412
SUTRO BIOPHARMA INC / STRO FAQ
What is the stock price of SUTRO BIOPHARMA INC today?
The current stock price of STRO is 1.77 USD. The price decreased by -3.28% in the last trading session.
What is the ticker symbol for SUTRO BIOPHARMA INC stock?
The exchange symbol of SUTRO BIOPHARMA INC is STRO and it is listed on the Nasdaq exchange.
On which exchange is STRO stock listed?
STRO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SUTRO BIOPHARMA INC stock?
17 analysts have analysed STRO and the average price target is 11.73 USD. This implies a price increase of 562.71% is expected in the next year compared to the current price of 1.77. Check the SUTRO BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SUTRO BIOPHARMA INC worth?
SUTRO BIOPHARMA INC (STRO) has a market capitalization of 145.95M USD. This makes STRO a Micro Cap stock.
How many employees does SUTRO BIOPHARMA INC have?
SUTRO BIOPHARMA INC (STRO) currently has 304 employees.
What are the support and resistance levels for SUTRO BIOPHARMA INC (STRO) stock?
SUTRO BIOPHARMA INC (STRO) has a resistance level at 1.88. Check the full technical report for a detailed analysis of STRO support and resistance levels.
Is SUTRO BIOPHARMA INC (STRO) expected to grow?
The Revenue of SUTRO BIOPHARMA INC (STRO) is expected to grow by 13.89% in the next year. Check the estimates tab for more information on the STRO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SUTRO BIOPHARMA INC (STRO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STRO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STRO, evaluating the profitability, health, valuation and growth aspects
- SUTRO BIOPHARMA INC (STRO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SUTRO BIOPHARMA INC (STRO) Sales and EPS estimates to see what analysts future expectations are.
- SUTRO BIOPHARMA INC (STRO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SUTRO BIOPHARMA INC (STRO) Insider and Institutional Ownership to learn about the owners and their transactions.
- SUTRO BIOPHARMA INC (STRO) Stock Chart to make your own analysis
- SUTRO BIOPHARMA INC (STRO) Latest news and press-releases to stay up to date.
Does SUTRO BIOPHARMA INC (STRO) stock pay dividends?
STRO does not pay a dividend.
When does SUTRO BIOPHARMA INC (STRO) report earnings?
SUTRO BIOPHARMA INC (STRO) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of SUTRO BIOPHARMA INC (STRO)?
SUTRO BIOPHARMA INC (STRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
What is the Short Interest ratio of SUTRO BIOPHARMA INC (STRO) stock?
The outstanding short interest for SUTRO BIOPHARMA INC (STRO) is 4.98% of its float. Check the ownership tab for more information on the STRO short interest.
STRO Technical Analysis
STRO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to STRO. While STRO seems to be doing ok healthwise, there are quite some concerns on its profitability.
STRO Financial Highlights
Over the last trailing twelve months STRO reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 45.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.43% | ||
| ROE | -111.45% | ||
| Debt/Equity | 0 |
STRO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to STRO. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -66.09% and a revenue growth 13.89% for STRO